Long non-coding RNAs as novel prognostic biomarkers for breast cancer in Egyptian women.

Autor: El-Helkan B; Department of Biochemistry, Faculty of Science-Ain Shams University, Cairo, Egypt., Emam M; Department of Biochemistry, Faculty of Science-Ain Shams University, Cairo, Egypt., Mohanad M; College of Pharmaceutical Sciences and Drug Manufacturing, Misr University for Science and Technology, 6th of October ,Giza, Egypt., Fathy S; Department of Biochemistry, Faculty of Science-Ain Shams University, Cairo, Egypt., Zekri AR; Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt., Ahmed OS; Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt. Ola.sayed@nci.cu.edu.eg.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2022 Nov 14; Vol. 12 (1), pp. 19498. Date of Electronic Publication: 2022 Nov 14.
DOI: 10.1038/s41598-022-23938-8
Abstrakt: Breast cancer (BC), the most common type of malignant tumor, is the leading cause of death, having the highest incidence rate among women. The lack of early diagnostic tools is one of the clinical obstacles for BC treatment. The current study was designed to evaluate a panel of long non-coding RNAs (lncRNAs) BC040587, HOTAIR, MALAT1, CCAT1, CCAT2, PVT1, UCA1, SPRY4-IT1, PANDAR, and AK058003-and two mRNAs (SNCG, BDNF) as novel prognostic biomarkers for BC. This study was ethically approved by the Institutional Review Board of the National Cancer Institute, Cairo University. Our study included 75 women recently diagnosed with BC and 25 healthy women as normal controls. Patients were divided into three groups: 24 with benign breast diseases, 28 with metastatic breast cancer (MBC, stage IV), and 23 with non-metastatic breast cancer (NMBC, stage III). LncRNA and mRNA expression levels were measured in patient plasma using quantitative real-time PCR. We found that 10 lncRNAs (BCO40587, HOTAIR, PVT1, CCAT2, PANDAR, CCAT1, UCA1, SPRY4-IT1, AK058003, and MALAT1) and both mRNAs demonstrated at least a 2-fold change in expression with a more than 95% probability of significance. BCO40587 and SNCG were significantly up-regulated in MBC and NMBC patients (3.2- and 4-fold, respectively) compared with normal controls. The expression of UCA1 was repressed by 1.78-fold in MBC and NMBC patients compared with those with benign diseases. SPRY4-IT1 was down-regulated by 1.45-fold in MBC patients compared with NMBC and benign disease patients. Up-regulation of lncRNAs plays an important role in BC development. SNCG and BCO40587 may be potential prognostic markers for BC.The organization number is IORG0003381 (IRB No: IRB00004025).
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje